BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

The German biotech provides a weak full-year outlook and announces the exit of its co-founders.

BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

BioNTech (BNTX) stock tumbles 17% after reporting Q4 losses, missing 2026 revenue projections, and announcing co-founder departures. Full analysis here.

For the fiscal fourth quarter ending in December, Germany-based BioNTech turned €907.4 million in revenue into an adjusted per-share loss of €0.33. Both were down from year-ago comparisons, when ...

BioNTech SE reports fourth-quarter and full-year 2025 results Tuesday before the market opens, confronting investors with a stark contrast: plunging COVID-19 vaccine sales against ambitious oncology ...

In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğu | Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife and CMO Özlem Türeci to establish ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine. (March 10): BioNTech SE’s founders will leave ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...